Examining Challenges to Antibiotic Commercialization in International Markets

Access to new antibiotics is important to maintain public health, particularly as antimicrobial resistance (AMR) increases across the globe. However, companies face a variety of barriers in the commercialization of new antibiotics, which may influence what countries gain access to these drugs. Many countries, including the US, UK, and Sweden, are modifying or exploring approaches to modify the way that antibiotics are reimbursed. These changes will have broad implications for payment and access across healthcare systems, and may benefit from better alignment of payment approaches. This workshop is convened to consider circumstances impacting the commercialization of novel antibiotics among different nations and opportunities to align policy approaches for antibiotic reimbursement reform and development incentives.